U.S. RESEARCH ROUNDUP- Albemarle, Carmax, Kroger
U.S. RESEARCH ROUNDUP- Albemarle, Carmax, Kroger June 19 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Albemarle, Carmax and Kroger on Friday.
HIGHLIGHTS
* Albemarle ALB.N: JP Morgan raises target price to $160 from $145 |
* Carmax Inc KMX.N: Stephens raises to overweight from equal weight |
* Eli Lilly LLY.N: Berenberg raises target price to $1,135 from $1,050 |
* Kroger Co KR.N: Telsey Advisory Group cuts target price to $78 from $82 |
* Sunbelt Rentals Holdings Inc SUNB.N: RBC raises to sector perform from underperform |
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical order.
* A10 Networks Inc ATEN.N: BTIG raises target price to $37 from $30 |
* Albemarle ALB.N: JP Morgan raises target price to $160 from $145 |
* Carmax Inc KMX.N: Stephens raises target price to $66 from $43 |
* Carmax Inc KMX.N: Stephens raises to overweight from equal weight |
* Eli Lilly LLY.N: Berenberg raises target price to $1,135 from $1,050 |
* Kroger Co KR.N: BMO cuts target price to $60 from $70 |
* Kroger Co KR.N: Jefferies cuts target price to $74 from $80 |
* Kroger Co KR.N: JP Morgan cuts target price to $63 from $70 |
* Kroger Co KR.N: Telsey Advisory Group cuts target price to $78 from $82 |
* Sunbelt Rentals Holdings Inc SUNB.N: RBC raises target price to $80 from $62 |
* Sunbelt Rentals Holdings Inc SUNB.N: RBC raises to sector perform from underperform |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Recent news on Eli Lilly and Co
See all newsAntares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Absci rises on positive hair-loss drug data
China approval for Eli Lilly GLP-1 pill to come as soon as 2026, executive says
HK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)